業績（論文・著書）
2024年
1. Biniaris-Georgallis SI, Aschman T, Stergioula K, et al. Amplification of autoimmune organ damage by NKp46-activated ILC1. Nature. 2024
2. Ishikawa Y, Tanaka N, Asano Y, et al. GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region. Nat Commun. 2024; 15(1) :319.
3. Cano E, Schwarzkopf J, Kanda M, et al. Intramyocardial Sprouting Tip Cells Specify Coronary Arterialization. Circ Res. 2024.
4. Nakamura H, Tanaka T, Zheng C, et al. Amplified Type I Interferon Response in Sjögren’s Disease via Ectopic Toll-Like Receptor 7 Expression in Salivary Gland Epithelial Cells Induced by Lysosome-Associated Membrane Protein 3. Arthritis Rheumatol. 2024; 76(7): 1109.
5. Maeda A, Tsuchida N, Uchiyama Y, et al. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome. Rheumatology (Oxford). 2024; 63(8): 2056.
6. Sugawara M, Osanami A, Asai Y, et al. Successful treatment of ANCA-associated glomerulonephritis following pulmonary alveolar proteinosis by rituximab and avacopan. Rheumatology (Oxford).2024; 63(2): e51-e52.
7. Tada M, Kudo Y, Kono M, Kanda M, et al. Itaconate reduces proliferation and migration of fibroblast-like synoviocytes and ameliorates arthritis models.Clin Immunol.2024; 110255.
8. Kanda M, Sato M, Nagahata K, et al. Assessment of oral methotrexate intolerance in Japanese adult patients with rheumatoid arthritis.Int J Rheum Dis.2024; 27(1): e15029.
9. Nakamura H, Nagahata K, Amaike H, et al. Case report: Autoinflammatory manifestations in a patient with Sjögren's disease.Int J Rheum Dis.2024; 27(2): e15083.
10. Amaike H, Nagahata K, Kanda M, et al. Case report: Lymphocyte-variant hypereosinophilic syndrome with dense IgG4-positive plasma cell infiltration of lymph nodes.Int J Rheum Dis.2024; 27(6): e15206.
11. Mizushima I, Morikage N, Ito E, et al. Validation of the Diagnostic Criteria for IgG4-Related Periaortitis/Periarteritis and Retroperitoneal Fibrosis (IgG4PA/RPF) 2018, and Proposal of a Revised 2023 Version for IgG4-Related Cardiovascular/Retroperitoneal Disease.Circ J.2024; 88(10): 1679.
12. Yoshikawa Y, Oura S, Kanda M, et al. Comparison of the negative effect of remimazolam and propofol on cardiac contractility: Analysis of a randomised parallel‐group trial and a preclinical ex vivo study.Clin Exp Pharmacol Physiol.2024; 51(3): e13840.
13. Nagahata K, Kawakami Y, Nakase H. Invisible pancreatic cancer: the cuff sign. QJM.2024; 117(7): 525.
14. Nagahata K, Murase K, Kanda M, Takahashi H. Bloody Diarrhea in a 27-year-old Man with Adult-onset Stills Disease.JMA J.2024; 7(1): 127-129.
15. Nagahata K, Hagino N. Unusual pleural effusion in a patient with rheumatoid arthritis: chylothorax. Clin Rheumatol. 2024; 43(2): 809.
16. Nagahata K, Yano T, Takahashi H. A fried egg sign: a rare presentation of periaortitis in a patient with granulomatosis with polyangiitis. Clin Rheumatology.2024.
17. 高橋裕樹，永幡研.「涙腺・唾液腺病変」日本臨床.2024: 82 (3), 364-369.
18. 高橋裕樹，中村浩之.「シェーグレン症候群」呼吸器内科. 2024; 46 (2): 144-150.
19. 神田真聡.「IgG4関連疾患における超音波画像検査」日本臨床.2024; 82(3): 358-363.
20. 永幡研ら.「第3章 難治性関節リウマチに挑む (6. 高齢者の関節リウマチ)」あなたも名医！ピンチを乗り切る関節リウマチ診療 (萩野昇編). 2024.
21. 神田真聡、亀倉隆太、菅原正成ら.「デュピルマブを投与したIgG4関連疾患のケースシリーズ」札幌医学雑誌. 2024; 93(1-6): 86-87
2023年
1. Kanda M, Kamekura R, Sugawara M, et al. IgG4-related disease administered dupilumab: case series and review of the literature.RMD open.2023; 9(1): e003026.
2. Aso K, Kono M, Kanda M, et al. Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming.Nat Commun.2023; 14(1): 984.
3. Nakazawa D, Takeda Y, Kanda M, et al. Inhibition of Toll-like receptor 4 and Interleukin-1 receptor prevent SARS-CoV-2 mediated kidney injury.Cell Death Discov.2023; 9(1): 293.
4. Nakazawa D, Takeda Y, Kanda M, et al. Transcriptional dynamics of granulocytes in direct response to incubation with SARS-CoV-2.FEBS Open Bio.2023: 13(1): 60-71
5. Kumagai J, Kiuchi M, Kokubo K, et al. The USP7-STAT3-granzyme-Par-1 axis regulates allergic inflammation by promoting differentiation of IL-5-producing Th2 cells. Proc Natl Acad Sci U S A.2023; 120(49): e2302903120.
6. Shiratori-Aso S, Nakazawa D, Kudo T, Kanda M, et al. CD47 blockade ameliorates autoimmune vasculitis via efferocytosis of neutrophil extracellular traps.JCI Insight.2023; 8(15): e167486.
7. Sakiyama K, Abe N, Fujieda Y, et al. Dynamics of corticocortical brain functional connectivity relevant to therapeutic response to biologics in inflammatory arthritis.Cereb Cortex.2023; 33(13): 8342.
8. Karino K, Kono M, Takeyama S, et al. Inhibitor of NF-kappaB Kinase Subunit epsilon Contributes to Neuropsychiatric Manifestations in Lupus-Prone Mice Through Microglial Activation.Arthritis Rheumatol.2023; 75(3): 411-423.
9. Kudo T, Nakazawa D, Watanabe-Kusunoki K, Kanda M, et al. Regulation of NETosis and Inflammation by Cyclophilin D in Myeloperoxidase-Positive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Arthritis Rheumatol.2023; 75(1): 71-83.
10. Nagahata K, Kamiya H, Takahashi H. A Rapidly progressive aortic aneurysm due to Escherichia Coli.Am J Med.2023; 136(6): e109.
11. Nagahata K, Suzuki C, Takahashi H. Spurious macrocytic anemia in a patient with systemic lupus erythematosus: cold agglutinin disease.Clin Rheumatology.2023; 42(5): 1485.
12. Nagahata K, Sugawara M, Kanda M, Takahashi H. Unrecognized pneumatosis intestinalis in anti-melanoma differentiation-associated gene 5 antibody-associated dermatomyositis.J Rheumatol.2023; 50(6): 846.
13. Nakamura K, Kanda M, Notohara K, et al. A tumefactive fibroinflammatory lesion of the head and neck mimicking immunoglobulin G4-related disease.Intern Med.2023; 62(4): 637.
14. Nagahata K, Osanami A, Nakamura H, et al. IgG4-related tubulointerstitial nephritis: Renal capsule-like rim.QJM.2023; 116(11): 953-954.
15. Takahashi K, Yoshikawa Y, Kanda M, et al. Dexmedetomidine as a cardioprotective drug: a narrative review.J Anesth.2023; 37(6): 961-970.
16. Watanabe A, Shima Y, Takahashi H, et al. Arm heating to relieve Raynaud's phenomenon in systemic sclerosis: A single-arm multicentre prospective clinical trial.Mod Rheumatol.2023; 35(3): 968-974.
17. 神田真聡, 永幡研, 遠藤知之ら.「CPC～何がおきていたのか?最終病理診断からのメッセージ～Sjögren症候群の加療中，発熱と血球減少を生じ死亡した1例」日本内科学会雑誌.2023; 112(9): 1786.
18. 高橋裕樹.「IgG4関連疾患の診断と治療」別冊BIO Clinica.2023; 12(2): 48.
19. 高橋裕樹, 永幡研, 神田真聡.「全身性強皮症の分類基準」リウマチ科.2023; 69(5): 509.
20. 高橋裕樹.「全身性硬化症(強皮症)」 今日の治療指針 私はこう治療している (福井次矢ほか総編).2023; p881-883.
2022年
1. Nagahata K, Kanda M, Kamekura R, et al. Abnormal [18F] fluorodeoxyglucose accumulation to tori tubarius in IgG4-related disease.Ann Nucl Med.2022; 36(2): 200.
2. Murayama K, Ikegami I, Kamekura R, et al. CD4(+)CD8(+) T follicular helper cells regulate humoral immunity in chronic inflammatory lesions.Front Immunol.2022; 13: 941385.
3. Ohwada S, Akutsu N, Masaki Y, et al. Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome Precedes the Development of Hepatocellular Carcinoma.JMA J. 2022; 5(3): 393-397.
4. Takano K, Kurose M, Kamekura R, Kanda M, Yamamoto M, Takahashi H. Tubarial gland involvement in IgG4-related diseases.Acta Otolaryngol.2022; 142(7-8): 616-619.
5. Yoshimura M, Fujieda Y, Sugawara M, et al. Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case-control study.Rheumatol Int.2022; 42(11): 1939-1946.
6. Abe N, Fujieda Y, Tha KK, et al. Aberrant functional connectivity between anterior cingulate cortex and left insula in association with therapeutic response to biologics in inflammatory arthritis.Semin Arthritis Rheum.2022; 151994.
7. Reichart D, Lindberg EL, Maatz H, et al. Pathogenic variants damage cell composition and single cell transcription in cardiomyopathies.Science.2022; 377(6606): eabo1984.
8. Nagahata K, Suzuki S, Yokochi R, et al. Recurrent Optic Perineuritis With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Complicated With Granulomatous Polyangiitis.Cureus.2022; 14(5): e25239.
9. Nagahata K, Muranaka A, Sugawara M, et al. Insidious pulmonary artery stenosis in Takayasu arteritis.QJM.2022; 115(6): 399.
10. Osanami A, Kanda M, Sato T, et al. Case report: Successful combination therapy with double-filtration plasmapheresis and rituximab under the condition of the use of a sensor-augmented pump for type B insulin resistance syndrome.Front Endocrinol (Lausanne).2022; 13: 997296.
11. 高橋裕樹, 永幡研, 神田真聡.「IgG4関連疾患」日本臨床.2022; 80(10): 1581-1587.
12. 高橋裕樹, 鈴木知佐子, 神田真聡.「IgG4関連疾患の診断のポイント」リウマチ科.2022; 68(3): 275-280.
2021年
1. Umehara H, Okazaki K, Kawa S, Takahashi H, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD.Mod Rheumatol.2021; 31(3): 529-533.
2. Sugawara M, Fujieda Y, Noguchi A, et al.. Prediction of non-responder to JAK inhibitors in patients with rheumatoid arthritis: a preliminary study with integrative cluster analysis.Clin Exp Rheumatol.2021; 40(9): 1674-1680.
3. 高橋裕樹, 鈴木知佐子, 神田真聡.「IgG4関連疾患の歴史」臨床免疫・アレルギー科.2021; 75(4): 416-421.
4. 高橋裕樹.「IgG4関連涙腺・唾液腺炎の長期経過」医のあゆみ.2021; 276: 131-134.
5. 高橋裕樹, 神田真聡.「IgG4関連疾患の治療」Medical Practice.2021; 38: 444-448.
6. 梅原久範, 岡崎和一, 川茂幸, 高橋裕樹ら.「2020年改訂IgG4関連疾患包括診断基準」日内会誌.2021; 110(5): 962-969.
7. 高橋裕樹.「IgG4関連疾患」今日の治療指針 私はこう治療している (福井次矢ほか総編).2021; p918-920.
8. 高橋裕樹.「IgG4関連疾患」今日の整形外科治療指針 第8版 (土屋弘行ほか編).2021; p197.
2020年
1. Kameda M, Otsuka M, Chiba H, et al. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features.PLoS ONE.2020; 15(11): e04241719.
2. Litviňuková M, Talavera-López C, Maatz H, et al. Cells of the adult human heart.Nature.2020; 588(7838): 466-472.
3. 高橋裕樹.「IgG4関連疾患における濾胞ヘルパーT細胞」臨床免疫・アレルギー科.2020; 73 (3): 235-240.
2019年
1. Yamamoto M, Takano KI, Kamekura R, et al. Analysis of allergic reaction in IgG4-related disease.Mod Rheumatol.2019; 29(6): 1063-1065.
2. Ito F, Kamekura R, Yamamoto M, et al. IL-10+ T follicular regulatory cells are associated with the pathogenesis of IgG4-related disease.Immunol Lett.2019; 207: 56-63.
3. Yamamoto M, Takahashi H, Tanaka H. Differences in clinical features of immunoglobulin G4-related disease between older and younger patients.Geriatr Gerontol Int.2019; 19(6): 564-565.
4. Terao C, Ota M, Iwasaki T, et al. IgG4-related disease in the Japanese population: a genome-wide association study.Lancet Rheumatology.2019; 1(1): e14-e22.
5. 高橋裕樹, 鈴木知佐子.「免疫・膠原病領域におけるIgG4関連疾患研究の過去・現在・未来」消化器病学サイエンス.2019; 3(3): 157-160.
6. 高橋裕樹.「IgG4関連疾患は自己免疫現象か」臨床免疫・アレルギー科.2019; 71(5): 472-476.
7. 高橋裕樹.「唾液腺病変 治療と予後」最新IgG4関連疾患 改訂第2版 (岡崎和一・川茂幸編).2019; p66-69.
8. 高橋裕樹.「全身性硬化症（強皮症）」今日の治療指針 私はこう治療している (福井次矢ほか総編).2019; p880-884.
9. 高橋裕樹.「IgG4関連疾患」内科学書 改訂第9版 (南学正臣編).2019; p307-313.
2018年
1. Yamamoto M, Takano K, Kamekura R, et al. Predicting therapeutic response in IgG4-related disease based on cluster analysis.Immunol Med.2018; 41: 30-33.
2. Yamamoto M, Takano KI, Takahashi H. Early therapeutic intervention for IgG4-relaed dacryoadenitis and sialadenitis: the balance between risk of observation only and therapeutic adverse effects.J Rheumatol.2018; 45: 1339-1340.
3. Yamamoto M, Takano K, Kamekura R, et al. Stage classification of IgG4-related dacryoadenitis and sialadenitis by the serum cytokine environment.Mod Rheumatol.2018; 28: 1004-1008.
4. Takano K, Yajima R, Kamekura R, et al. Clinical utility of 18 F-fluorodeoxyglucise/positron emission tomography in diagnosis of immunoglobulin G4-related sclerosing sialadenitis.Laryngoscope.2018; 128: 1120-1125.
5. Shirakashi M, Yoshifuji H, Kodama Y, et al. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicenter study.Sci Rep.2018; 8: 10262.
6. Yano T, Yamamto M, Mochizuki A, et al. Successful transcatheter diagnosis and medical treatment of right atrial involvement in IgG4-related disease.Int Heart J.2018; 59: 1155-1160.
7. 山本元久, 髙橋裕樹.「シェーグレン症候群の診断」Entoni.2018; 222: 29-36.
8. 山本元久, 鈴木知佐子, 髙橋裕樹.「IgG4関連疾患に対するアバタセプトの長期寛解維持効果の可能性」リウマチ科.2018; 59: 441-448．
9. 山本元久, 髙橋裕樹.「頭頸部領域のIgG4関連疾患の臨床像」リウマチ科.2018; 60: 359-365.
10. 髙橋裕樹, 鈴木知佐子, 山本元久.「IgG4関連疾患の治療」リウマチ科.2018; 60: 403-409.
11. 山本元久, 髙橋裕樹.「IgG4関連疾患」整形・災害外科.2018; 61: 937-945．
12. 髙橋裕樹.「IgG4関連疾患」アレルギーの臨床.2018; 38: 753-756．
13. 髙橋裕樹, 鈴木知佐子, 山本元久.「IgG4関連疾患 治療」シェーグレン症候群の診断と治療マニュアル 改定第3版.2018; p199-204.
14. 髙橋裕樹.「IgG4関連疾患」最新医学 別冊 診断と治療のABC 139 (田中良哉編集).2018; p170-178.
2017年
1. Takano K, Yamamoto M, Ichimiya S, et al. Assessing the usefulness of salivary gland biopsy for diagnosis of type-1 autoimmune pancreatitis.Mod Rheumatol.2017; 27: 548-550.
2. Kamekura R, Takano K, Yamamoto M, et al. A critical role of lesional T follicular helper cells in the pathogenesis of IgG4-related disease .J Immunol.2017; 199: 2624-2629.
3. Yamada K, Yamamoto M, Saeki T, et al. New clues to the nature of immunoglobulin G4-related disease: a retrospective Japanese multicenter study of baseline clinical features of 334 cases.Arthritis Res Ther.2017; 19: 262.
4. Takano K, Yamamoto M, Takahashi H, Himi T. Recent advances in knowledge regarding the head and neck manifestations of IgG4-related disease.Auris Nasus Larynx.2017; 44: 7-17.
5. 山本元久, 髙橋裕樹.「治療効果からみた病因病態」臨床免疫・アレルギー科.2017; 67: 354-359.
6. 山本元久, 髙橋裕樹.「IgG4関連涙腺・唾液腺炎（ミクリッツ病）の診療とトピックス」臨床リウマチ.2017; 29: 147-154．
7. 山本元久.「診療の秘訣 IgG4関連疾患に対する治療とモニタリング」Modern Physician.2017; 37: 1008．
8. 髙橋裕樹, 鈴木知佐子, 山本元久.「IgG4関連疾患の診断と治療」血液内科.2017; 75: 618-624.
9. 高橋裕樹.「IgG4関連疾患」矢崎義雄 総編集 内科学 第11版.2017; p1293-1295.
10. 高橋裕樹, 鈴木知佐子, 山本元久.「IgG4関連疾患」分子リウマチ治療.2017; 10: 41-45.
2016年
1. Yamamoto M, Takahashi H, Takano K, et al. Efficacy of abatacept for IgG4-related disease over eight months.Ann Rheum Dis.2016; 75: 1576-1578.
2. Yamamoto M, Yokoyama Y, Shimizu Y, et al. Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis.Mod Rheumatol.2016; 26: 633-634.
3. Yamamoto M, Takahashi H. IgG4-related disease in organs other than the hepato-biliary-pancreatic system.Semin Liver Dis.2016; 36: 274-282.
4. Takano K, Nomura K, Abe A, et al. Clinicopathological analysis of salivary gland tissue from patients with IgG4-related disease.Acta Otolaryngol.2016; 136: 717-721.
5. Mizushima I, Yamamoto M, Inoue D, et al. Factors related to renal cortical atrophy development after glucocorticoid therapy in IgG4-related kidney disease: a retrospective multicenter study.Arthritis Res Ther.2016; 18: 273.
6. Abe A, Takano K, Kojima T, et al. Interferon-gamma increased epithelial barrier function via upregulating claudin-7 expression in human submandibular gland duct epithelium.J Mol Histol.2016; 47: 353-363.
7. Shimizu Y, Yamamoto M, Yajima H, et al. Role of interleukin-32 in the mechanism of chronic inflammation in IgG4-related disease and as a predictive biomarker for drug-free remission.Mod Rheumatol. 2016; 26: 391-397.
8. 山本元久, 高橋裕樹.「医療現場でのふるまい方 他科との連携」膠原病・リウマチ・アレルギー研修医ノート.2016; p32-34.
9. 山本元久, 高橋裕樹.「リツキシマブを含む分子標的薬の使用経験」肝胆膵.2016; 73: 607-614.
10. 山本元久.「私の処方 IgG4関連疾患に対する寛解導入療法」Modern Physician.2016; 36: 1219.
11. 山本元久.「IgG4関連疾患に対する新たな治療戦略」日臨免誌.2016; 39: 485-490.
12. 山本元久, 高橋裕樹.「IgG4関連疾患におけるアレルギーの関与」アレルギーの臨床.2016; 36: 1241-1244.
13. 鈴木知佐子, 高橋裕樹.「造血幹細胞移植」強皮症の基礎と臨床 病態の解明から最新の診療まで.2016; p241-247.
14. 高橋裕樹, 鈴木知佐子, 山本元久.「Mikulicz病」診断と治療.2016; 104: 433-8．
15. 高橋裕樹, 山本元久.「IgG4関連涙腺・唾液腺炎の最新の知見」医学のあゆみ.2016; 258: 233-236.